Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting

This is a randomized, open-label, multi-center, phase 4 study. The overall goals of this
study are to compare intravenous (IV) daptomycin and IV vancomycin administered in a home
infusion setting for the treatment of cSSSI due to Gram-positive bacteria in participants who
are prescribed vancomycin for 7-14 days and who are planning to receive vancomycin in a home
infusion setting. Study objectives include evaluation of clinical and resource utilization
endpoints and economic analysis from the perspective of the home infusion provider.

Inclusion Criteria:

- Complicated skin or skin structure infection (cSSSI)

- Intravenous vancomycin home infusion ordered for 7-14 days

Exclusion Criteria:

- Pregnant or lactating female

- Concurrently receiving other systemic antibiotics with gram positive activity

- Known or suspected allergy or hypersensitivity to daptomycin or vancomycin

- Known or suspected vancomycin-resistant enterococci (VRE)

- Known or suspected osteomyelitis, pneumonia, bacteremia, endocarditis, or urinary
tract infection

- Known or suspected human immunodeficiency virus (HIV), cancer, or autoimmune disease
such as lupus

- Receiving systemic concomitant immunosuppressive agents such as chemotherapy,
corticosteroids, tacrolimus, sirolimus, or cyclosporine, during the duration of the
study

- Requirement for non-study gram positive systemic antibiotics

- Known to be allergic or intolerant to intravenous vancomycin or daptomycin

- Participants with known or suspected creatinine clearance (CLcr) < 30 milliliters per
minute (mL/min)

- In skilled nursing facility

- In hospice or admission to hospice is planned